Association of clinician knowledge and statin beliefs with statin therapy use and lipid levels (A Survey of US Practice in the PALM Registry)

Authors

Angela Lowenstern, Duke University School of Medicine, USA.
Ann Marie Navar, Duke University School of Medicine, USA.
Shuang Li, Duke Clinical Research Institute, USA.
Salim S. Virani, Baylor College of Medicine, USA.Follow
Anne C. Goldberg, Washington University, USA.
Michael J. Louie, Regeneron Pharmaceuticals, Inc., USA.
L Veronica Lee, Sanofi Pharmaceutical Company, USA.
Eric D. Peterson, Duke University School of Medicine, USA.
Tracy Y. Wang, Duke University School of Medicine, USA.

Document Type

Article

Department

Cardiology; Office of the Provost

Abstract

Guideline implementation requires clinician knowledge but may be influenced by pre-existing beliefs and biases. We assessed the association of these clinician factors with lipid management following the release of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines. In the PALM registry, 774 clinicians completed a survey to assess their knowledge of the 2013 American College of Cardiology/American Heart Association guidelines, belief in statin benefit, and statin safety concerns. The association of these factors with statin use, statin dosing, and low-density lipoprotein cholesterol (LDL-C) levels were assessed in the 6,839 patients treated by these clinicians between May and November 2015. Overall, 63.9% of clinicians responded to at least 3 out of 4 hypothetical scenarios in concordance with guideline recommendations (good tested knowledge), 88.4% reported belief in statin benefit, and 15.4% raised concerns about statin safety. Belief in statin benefit was more prevalent among cardiologists, who represented 48.8% of the clinicians surveyed, and concerns regarding statin safety were higher among noncardiologists and clinicians in an academic setting. Guideline knowledge was not associated with a difference in statin use (74.1% vs 73.8%, p = 0.84) and achievement of LDL-C level <100 mg/dl (54.7% vs 52.4%, p = 0.07). However, patients treated by clinicians who reported belief in statin benefit were more likely to receive guideline-recommended statin intensity (41.9% vs 36.9%, p = 0.03), whereas patients treated by clinicians expressing statin safety concerns were less likely receive statins of at least guideline-recommended intensity (36.8% vs 42.5%, p = 0.001) and to achieve an LDL-C <100 mg/dl (44.1% vs 56.1%, p <0.001); the latter persisted after multivariable adjustment (odds ratio 0.75, 95% confidence interval 0.63 to 0.89). In conclusion, clinician beliefs regarding benefits and risks of statins were significantly associated with guideline adherence and patients' achieved LDL-C levels, whereas clinician knowledge of guideline recommendations was not.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

The American Journal of Cardiology

DOI

10.1016/j.amjcard.2018.12.031

Recommended Citation

Lowenstern, A., Navar, A. M., Li, S., Virani, S. S., Goldberg, A. C., Louie, M. J., Lee, L. V., Peterson, E. D., Wang, T. Y. (2019). Association of clinician knowledge and statin beliefs with statin therapy use and lipid levels (A Survey of US Practice in the PALM Registry). The American Journal of Cardiology, 123(7), 1011-1018.
Available at: https://ecommons.aku.edu/provost_office/660